Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: An intergroup, multicenter, phase II study

Annals of Oncology

Volumn 15, Issue 2, 2004, Pages 224-229

  Stathopoulos, G P ^a,b,c   Syrigos, K ^a   Polyzos, A ^a   Fountzilas, G ^b   Rigatos, S K ^a   Ziras, N ^a   Potamiannou, A ^a   Tsiakopoulos, I ^a   Androulakis, N ^a   Aravantinos, G ^b   Athanasiadis, A ^a   Papakotoulas, P ^a   Georgoulias, V ^a  

^a Hellenic Oncology Research Group   (Greece)

^b Hellenic Cooperative Oncology Group   (Greece)

^c NONE   (Greece)

Author keywords

Capecitabine; Gemcitabine; Pancreatic cancer

Indexed keywords

CAPECITABINE; FLUOROURACIL; GEMCITABINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BODY WEIGHT DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HUMAN; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TUMOR DIFFERENTIATION; TUMOR GROWTH; WEIGHT GAIN;

ADENOCARCINOMA; ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 10744225818     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh065     Document Type: Article

References (25)

1. Burris HA III, Moore MJ, Anderson J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-2413.
2. Casper ES, Green MR, Kelsen DP. Phase II trial of gemcitabine (2.2 difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29-34.
3. Schnall SF, MacDonald JS. Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 1996; 23: 220-228.
4. Hidalgo M, Castellano D, Paz-Ares L et al. Phase I-II study of Gemcitabine and Fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999; 17: 585-592.
5. Wagener DJT, Verdonk HER, Dirix LY et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer. An EORTC Early Clinical Trials Group study. Ann Oncol 1995; 6: 129-133.
6. Kostandoulakis MM, Antonakis PT, Tsibloulis BG et al. A phase II study of 9-nitro-camptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2001; 48: 417-420.
7. Carmichael J, Fink U, Russel RCG et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 73: 101-106.
8. Heinemann V, Wilke H, Mergenthaler HG et al. Gemcitabine and Cisplatin in the treatment of advanced and metastatic pancreatic cancer. Ann Oncol 2000; 11: 1399-1403.
9. Alberts SR, Twonley, PM, Goldberg RM et al. Gemcitabine and oxaliplatin for patients with advanced or pancreatic metastatic cancer: A North Central Cancer Treatment Group (NCCTG) phase I study. Ann Oncol 2002; 13: 553-557.
10. Androulakis N, Kouroussis CH, Dimopoulos MA et al. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: A multicenter phase II study. J Clin Oncol 1999; 17: 1779-1785.
11. Stathopoulos GP, Mavroudis D, Tsavaris N et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2001; 12: 101-103.
12. Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma. Eastern Cooperative Oncology Group Trial E 2297. J Clin Oncol 2002; 20: 3270-3275.
13. Shulman KL, Kindler HL, Lad TE et al. Phase II study of gemcitabine (G) and continuous intravenous infusion (CIV) 5-fluorouracil (5-FU) in advanced pancreatic cancer (PC) consortium study. Proc Am Soc Clin Oncol 2000; 19; 288a (Abstr 1126).
14. Polyzos A, Tsavaris N, Cosmas C et al. A phase II study of Gemcitabine (GEM) plus 5-fluorouracil (5-FU) modulated by Leucovorin (LV) for advanced pancreatic cancer. Proc Am Soc Clin Oncol 2000; 19: 311a (Abstr 1229).
15. Rougier PH, Paillot B, La Planche A et al. 5-Fluorouracil (5-FU) continuous infusion compared with bolus administration. Final results of a randomized trial in metastatic colorectal cancer. Eur J Cancer 1997; 33: 1789-1793.
16. Ishitcuka IL, Miwq M, Ishikawa T et al. Capecitabine: An orally available fluoropyrimide with tumor selective activity. Proc Am Soc Cancer Res 1995; 36: 407 (Abstr 2426).
17. Mackean M, Plating A, Twelves C et al. Phase I and pharmacologic study in intermittent twice-daily therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 2002; 20: 160-164.
18. Cartwright TH, Cohn A, Varkey JA et al. A phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002; 20: 160-164.
19. Hess V, Salzberg M, Borner M et al. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: A phase I/II trial. J Clin Oncol 2003; 21: 66-68.
20. Herrmann R, Bormer M, Morant R et al. Combining gemcitabine (GEM) and capecitabine (CAP) in advanced pancreatic cancer. Results of a phase I trial. Proc Am Soc Clin Oncol 2000; 19: 267a (Abstr 1038).
21. Miller AB, Hoogstraten B, Staqnet M. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
22. Ren Q, Kao V, Grem JL. Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2-deoxyuridine in HT-29 colon cancer cells. Clin Cancer Res 1998; 4: 2811-2818.
23. Stathopoulos GP, Rigatos SK, Dimopoulos MA et al. Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: A multicenter phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2003; 14: 388-394.
24. Halm U, Schumann T, Schictke I et al. Decrease of CA-19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000; 82: 1013-1016.
25. Scheithauer W, Schüll B, Ulrich-Pur H et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase III trial. Ann Oncol 2003; 14: 97-104.